Recent 8-K filings for ARTL
Highest-materiality recent filing
Artelo raises ~$9.5M private placement to buy Solana; gets UK MHRA nod for Phase 1 trial
- Gross proceeds ~$9.475M from 593,252 shares at $10.20 plus prefunded warrants; also issues Market Priced ($10.20) and $50.00 warrants.
- Net proceeds from shares will be used to purchase SOL; warrant proceeds for working capital and additional SOL.
-
Artelo Biosciences launches $6.53M ATM program; Craft Capital files FINRA claim for $880K
Entered at-the-market offering agreement with H.C. Wainwright to sell up to $6.53M of common stock, with 3.0% commission.
-
Artelo Biosciences regains Nasdaq compliance; monitored for one year
Nasdaq confirmed compliance with Equity Rule (≥$2.5M stockholders' equity) and Annual Meeting Rule.
-
Artelo Biosciences closes $11M private placement; expects to regain Nasdaq compliance
Gross proceeds $11.0M from sale of 3.19M common shares (or pre-funded warrants) and 6.38M common warrants at $3.45/unit.
-
Artelo expands ART27.13 development for muscle preservation with GLP-1 therapies
ART27.13 to be evaluated as companion therapy to prevent muscle loss in patients on GLP-1 receptor agonists for weight reduction.
-
Artelo Biosciences raises $310k via 12% bridge notes with default conversion feature
Issued two 12% bridge notes totaling $350,300 principal ($237,300 Vanquish + $113,000 Boot) for net proceeds of $310,000 after $40,300 OID.
-
Artelo Biosciences completes 1-for-3 reverse split; FY2025 net loss $12.9M, going concern
1-for-3 reverse stock split effective March 10, 2026; shares reduced from 2.1M to ~708k.
-
Artelo Biosciences gets Nasdaq panel exception to cure listing deficiencies by March 30
Panel granted exception to regain compliance with $2.5M stockholders' equity rule by March 30, 2026.
-
Artelo enters up to $50M equity purchase facility with Square Gate; issues 292K commitment shares
Equity Purchase Agreement with Square Gate provides up to $25M initially, expandable to $50M at company's option.
-
Artelo Biosciences receives Nasdaq delisting notice for missing annual meeting deadline
Nasdaq notified Artelo on Jan 14, 2026 of non-compliance with the Annual Meeting Rule (5620(a)).
-
Artelo Biosciences receives Nasdaq delisting notice; plans to appeal
Received delist determination on Nov 19, 2025 for non-compliance with equity rule (min $2.5M stockholders' equity).
-
Artelo Biosciences settles with activist investor Daniel Farb; he withdraws board nominations
Daniel S. Farb and affiliates irrevocably withdraw director nominations for 2025 annual meeting (letter dated Sept 19, 2025).
-
Artelo Biosciences closes $3M public offering of common stock and pre-funded warrants
Closed underwritten offering of 640,924 shares at $4.40/share and 40,894 pre-funded warrants at $4.399 each.
-
Interim Phase 2 CAReS: ART27.13 patients gained 6.38% mean body weight vs placebo loss of -5.42% at 12 weeks.
-
Artelo raises ~$9.5M private placement to buy Solana; gets UK MHRA nod for Phase 1 trial
Gross proceeds ~$9.475M from 593,252 shares at $10.20 plus prefunded warrants; also issues Market Priced ($10.20) and $50.00 warrants.
-
1-for-6 reverse split effective June 13, 2025, reducing outstanding shares from 3,280,000 to ~546,667.
-
Artelo raises $1.425M in private placement; to use $250k proceeds to buy SOL
Gross proceeds ~$1.425M from private placement of shares, pre-funded warrants, and warrants.
-
Artelo Biosciences completes 1-for-6 reverse stock split; Nasdaq compliance regained
Effective 12:01 a.m. ET June 13, 2025; each 6 pre-split shares combine into 1 post-split share; outstanding shares reduced from 3,280,000 to ~546,667.
-
Artelo Biosciences notified by Nasdaq of equity deficiency; $652K vs $2.5M minimum
As of March 31, 2025, stockholders' equity was $652,000, below the $2.5M minimum required by Nasdaq Rule 5550(b)(1).
-
Artelo Biosciences raises $900k via convertible notes with 12% interest and warrants
Closed $900,000 convertible note offering; directors and management purchased $200,000 of the notes.
-
Received Nasdaq notice on April 23, 2025 for non-compliance with $1.00 minimum bid price requirement.
Materiality & sentiment trend
Max materiality 0.80 · Median 0.60 · Most common event other_material